SNU-423Homo sapiens (Human)Cancer cell line

Also known as: NCI-SNU-423, SNU423

🤖 AI SummaryBased on 10 publications

Quick Overview

Human hepatocellular carcinoma cell line with TERT promoter mutations and potential for cancer research.

Detailed Summary

SNU-423 is a human hepatocellular carcinoma (HCC) cell line established from a primary tumor. It exhibits TERT promoter mutations, which are frequently associated with HCC and may play a role in tumor progression. The cell line is used in studies related to cancer genetics, drug sensitivity, and molecular mechanisms of hepatocellular carcinoma. Research on SNU-423 contributes to understanding the genetic alterations and therapeutic targets in HCC. The cell line is part of various cancer cell line databases and has been characterized for its genomic and molecular features.

Research Applications

Cancer geneticsDrug sensitivityMolecular mechanisms of HCCTERT promoter mutations

Key Characteristics

TERT promoter mutationsHepatocellular carcinoma originGenomic and molecular characterization
Generated on 6/15/2025

Basic Information

Database IDCVCL_0366
SpeciesHomo sapiens (Human)
Tissue SourceLiver[UBERON:UBERON_0002107]

Donor Information

Age40
Age CategoryAdult
SexMale
Raceasian

Disease Information

DiseaseAdult hepatocellular carcinoma
LineageLiver
SubtypeHepatocellular Carcinoma
OncoTree CodeHCC

DepMap Information

Source TypeATCC
Source IDACH-000493_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53c.376-2A>GUnspecifiedSplice acceptor mutationfrom parent cell line SNU-423
MutationSimpleTERTc.1-124C>T (c.228C>T) (C228T)UnspecifiedIn promoterfrom parent cell line Hep-G2

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
11,12
D13S317
10,13
D16S539
9
D18S51
12,13
D19S433
14,16.2
D21S11
30
D2S1338
19,24
D3S1358
17
D5S818
10
D7S820
12
D8S1179
11,16
FGA
21,24
Penta D
9
Penta E
11,12
TH01
6,9
TPOX
8
vWA
15
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

A pharmacogenomic landscape in human liver cancers.";

Hui L.-J.

Cancer Cell 36:179-193.e11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.

Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.

Gastroenterology 157:760-776(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.

Cevik D., Yildiz G., Ozturk M.

World J. Gastroenterol. 21:311-317(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.

Nat. Commun. 4:2218.1-2218.7(2013).

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.

Xu J.-C.

Hepatology 58:706-717(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Biology of SNU cell lines.";

Ku J.-L., Park J.-G.

Cancer Res. Treat. 37:1-19(2005).

Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA.

Won Y.-J., Kim S.-T., Park J.-G.

Int. J. Cancer 67:898-902(1996).

Characterization of cell lines established from human hepatocellular carcinoma.

Song S.-Y., Kim W.-H., Ki C.-W., Kim Y.-I.

Int. J. Cancer 62:276-282(1995).